JP2023532904A5 - - Google Patents
Info
- Publication number
- JP2023532904A5 JP2023532904A5 JP2022580769A JP2022580769A JP2023532904A5 JP 2023532904 A5 JP2023532904 A5 JP 2023532904A5 JP 2022580769 A JP2022580769 A JP 2022580769A JP 2022580769 A JP2022580769 A JP 2022580769A JP 2023532904 A5 JP2023532904 A5 JP 2023532904A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding domain
- substitution
- domain binds
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047681P | 2020-07-02 | 2020-07-02 | |
| US63/047,681 | 2020-07-02 | ||
| PCT/US2021/040061 WO2022006380A2 (en) | 2020-07-02 | 2021-07-01 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532904A JP2023532904A (ja) | 2023-08-01 |
| JP2023532904A5 true JP2023532904A5 (https=) | 2024-07-03 |
Family
ID=77127075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580769A Pending JP2023532904A (ja) | 2020-07-02 | 2021-07-01 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230235005A1 (https=) |
| EP (1) | EP4175979A2 (https=) |
| JP (1) | JP2023532904A (https=) |
| KR (1) | KR20230035076A (https=) |
| CN (1) | CN116615440A (https=) |
| AR (1) | AR122863A1 (https=) |
| AU (1) | AU2021299552A1 (https=) |
| CA (1) | CA3184618A1 (https=) |
| IL (1) | IL299542A (https=) |
| MX (1) | MX2022016532A (https=) |
| TW (1) | TW202216745A (https=) |
| WO (1) | WO2022006380A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| WO2023133393A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
| WO2023151661A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 免疫缀合物及其用途 |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| WO2024008126A1 (en) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Il2 muteins and uses thereof |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| KR20250143339A (ko) * | 2023-02-06 | 2025-10-01 | 메르크 파텐트 게엠베하 | VHH-기반 NKp46 결합제 |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| US11492384B2 (en) * | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
| SG11202106700WA (en) * | 2019-01-07 | 2021-07-29 | Inhibrx Inc | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
-
2021
- 2021-07-01 US US18/002,613 patent/US20230235005A1/en active Pending
- 2021-07-01 JP JP2022580769A patent/JP2023532904A/ja active Pending
- 2021-07-01 KR KR1020237003798A patent/KR20230035076A/ko active Pending
- 2021-07-01 CA CA3184618A patent/CA3184618A1/en active Pending
- 2021-07-01 EP EP21748720.6A patent/EP4175979A2/en active Pending
- 2021-07-01 IL IL299542A patent/IL299542A/en unknown
- 2021-07-01 TW TW110124255A patent/TW202216745A/zh unknown
- 2021-07-01 MX MX2022016532A patent/MX2022016532A/es unknown
- 2021-07-01 AR ARP210101857A patent/AR122863A1/es unknown
- 2021-07-01 AU AU2021299552A patent/AU2021299552A1/en active Pending
- 2021-07-01 WO PCT/US2021/040061 patent/WO2022006380A2/en not_active Ceased
- 2021-07-01 CN CN202180053315.0A patent/CN116615440A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516557A5 (https=) | ||
| JP2023532904A5 (https=) | ||
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| Xu et al. | Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Choi et al. | A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity | |
| KR102629905B1 (ko) | 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조 | |
| US20130129723A1 (en) | Heterodimer Binding Proteins and Uses Thereof | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| US20220089722A1 (en) | Heterodimeric fusion protein | |
| CA3043652A1 (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| CN115836084A (zh) | 多特异性免疫调节剂 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| Brinkmann et al. | The making of multispecific immunoglobulins–a clinical perspective | |
| EP4349870A1 (en) | Anti-cd3 antibody variant, fusion protein, and application | |
| EP4688841A1 (en) | All-in-one agonistic antibodies | |
| RU2021123226A (ru) | Полипептиды, содержащие модифицированный полипептид il-2, и их применения | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2023219121A1 (ja) | 抗ｔａａ－抗ｃｄ３多重特異性抗体 | |
| TW202404638A (zh) | 抗ｔｓｐａｎ８－抗ｃｄ３雙特異性抗體之與ｐｄ－１訊息抑制劑之組合在癌治療的用途 | |
| JP2024522078A (ja) | 抗ｇｐｃ３及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 | |
| HK1182402A (zh) | 異二聚體結合蛋白及其應用 |